Document Type : Original Article
Authors
- . Naser Aslanabadi 1
- . Naser Safaie 2
- . Faezeh Shadfar 1
- . Mohammad Reza Taban-Sadeghi 1
- . Hossein Feizpour 1
- . Simin Ozar Mashayekhi 2
- . Hadi Hamishehkar 2
- . Naser Khezerlou Aghdam 1
- . Samaneh Dousti 1
- . Hossein Namdar 1
1 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Objective: Acute myocardial infarction (AMI) is one of the main leading causes of mortality
and morbidity. Reteplase is a fibrin‑specific thrombolytic which is used in the treatment
of AMI. There is a limited number of studies reporting the postmarketing adverse drug
reactions (ADRs) induced by reteplase. This study was aimed to examine the reteplase
pattern of ADR and its associated risk factors in patients with acute ST‑elevation myocardial
infarction.
Methods: A cross‑sectional, prospective study in an 8‑month period was done at the
University affiliated referral cardiovascular center. The Naranjo probability scale and World
Health Organization criteria for severity of ADRs were used for assessing the ADRs. The
linear regression and logistic regression tests were used to evaluate the correlation between
ADRs and risk factors.
Findings: The all 20 patients who received reteplase during the study period were entered.
The majority of patients (n = 17) experienced at least one ADR. The results showed that
the incidence of ADRs was mainly associated with gender and age, and the number of ADRs
was associated with the history of diabetes and taking anti‑diabetic agents. The gender was
the main predictor in the occurrence of ADRs (odds ratio: 32, 95% confidence interval:
1.38–737.45; P = 0.030).
Conclusion: The results showed that gender, age, diabetes mellitus, and using of anti‑diabetes
medications are the risk factors associated with the incidence of ADRs by reteplase.
Keywords
drug reactions in hospitalized patients: A meta‑analysis of
prospective studies. JAMA 1998;279:1200‑5.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK,
Walley TJ, et al. Adverse drug reactions as cause of admission
to hospital: Prospective analysis of 18 820 patients. BMJ
2004;329:15‑9.
3. Wu Z, Van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D.
Pharmacokinetics and coronary thrombolytic properties
of two human tissue‑type plasminogen activator variants
lacking the finger‑like, growth factor‑like, and first kringle
domains (amino acids 6‑173) in a canine model. J Cardiovasc
Pharmacol 1990;16:197‑203.
4. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P,
Forycki F, et al. More rapid, complete, and stable coronary
thrombolysis with bolus administration of reteplase compared
with alteplase infusion in acute myocardial infarction. RAPID
investigators. Circulation 1995;91:2725‑32.
5. BodeC, SmallingRW, BergG, BurnettC, LorchG, KalbfleischJM,
et al. Randomized comparison of coronary thrombolysis
achieved with double‑bolus reteplase (recombinant
plasminogen activator) and front‑loaded, accelerated
alteplase (recombinant tissue plasminogen activator) in
patients with acute myocardial infarction. The RAPID II
investigators. Circulation 1994;94:891‑8.
6. American College of Emergency Physicians; Society for
Cardiovascular Angiography and Interventions, O’Gara PT,
Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, et al. 2013
ACCF/AHA guideline for the management of ST‑elevation
myocardial infarction: A report of the American College
of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines. J Am Coll Cardiol
2013;61:e78‑140.
7. BodeC, SmallingRW, BergG, BurnettC, LorchG, KalbfleischJM,
et al. Randomized comparison of coronary thrombolysis
achieved with double‑bolus reteplase (recombinant
plasminogen activator) and front‑loaded, accelerated
alteplase (recombinant tissue plasminogen activator) in
patients with acute myocardial infarction. The RAPID II
investigators. Circulation 1996;94:891‑8.
8. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM,
Aylward P, et al. Survival outcomes 1 year after reperfusion
therapy with either alteplase or reteplase for acute myocardial
infarction: Results from the Global Utilization of Streptokinase
and t‑PA for Occluded Coronary Arteries (GUSTO) III Trial.
Circulation 2000;102:1761‑5.
9. A comparison of reteplase with alteplase for acute myocardial
infarction. The Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO III) Investigators. N Engl J Med
1997;337:1118‑23.
10. Hampton JR, Schroder R, Wilcox RG, Skene AM,
Meyer‑Sabellek W, Heikkila J, et al. Randomized double‑blind
comparison of reteplase double‑bolus administration with
streptokinase in acute myocardial infarction (INJECT): Trial
to investigate equivalence. Lancet 1995;346:329‑36.
11. Antman EM, Anbe DT, Armstrong PW, Bates ER,
Green LA, Hand M, et al. ACC/AHA guidelines for the
management of patients with ST‑elevation myocardial
infarction – Executive summary. A report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines (writing committee to revise the
1999 guidelines for the management of patients with acute
myocardial infarction). J Am Coll Cardiol 2004;44:671‑719.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA,
et al. A method for estimating the probability of adverse drug
reactions. Clin Pharmacol Ther 1981;30:239‑45.
13. ShahK, ApsangikarP, AlluJ, Chaudhry S. Clinical retrospective
and prospective evaluation of efficacy and safety of reteplase
in STEMI patients. Indian Med Gaz 2012;146:479-87.
14. Singh RK, Trailokya A, Naik MM. Post‑reteplase evaluation
of clinical safety and efficacy in Indian patients (Precise‑In
Study). J Assoc Physicians India 2015;63:30‑5.
15. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex‑related variations
in the frequency and characteristics of adverse drug reactions.
Int J Clin Pharmacol Ther Toxicol 1980;18:362‑6.
16. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD.
Age and sex distribution of suspected adverse drug reactions to
newly marketed drugs in general practice in England: Analysis
of 48 cohort studies. Br J Clin Pharmacol 1998;46:505‑11.
17. Retavase product insert monograph. Germany: Boehringer
Mannheim GmbH, Centocor, Inc.; 1999.
18. Thong BY, Tan TC. Epidemiology and risk factors for drug
allergy. Br J Clin Pharmacol 2011;71:684‑700.
19. O’Mahony MS, Woodhouse KW. Age, environmental factors
and drug metabolism. Pharmacol Ther 1994;61:279‑87.
20. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug
reactions in elderly patients. Br J Clin Pharmacol 2004;57:121‑6.
21. Zaman Huri H, Fun Wee H. Drug related problems in
type 2 diabetes patients with hypertension: A cross‑sectional
retrospective study. BMC Endocr Disord 2013;13:2.
)